JOP20210147A1 - صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه - Google Patents

صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Info

Publication number
JOP20210147A1
JOP20210147A1 JOP/2021/0147A JOP20210147A JOP20210147A1 JO P20210147 A1 JOP20210147 A1 JO P20210147A1 JO P20210147 A JOP20210147 A JO P20210147A JO P20210147 A1 JOP20210147 A1 JO P20210147A1
Authority
JO
Jordan
Prior art keywords
pharmaceutical compositions
crystalline
organic compound
salts
salt forms
Prior art date
Application number
JOP/2021/0147A
Other languages
Arabic (ar)
English (en)
Inventor
Syed Altaf
Shijie Zhang
Abira Ramakrishnan
Jacob Sizemore
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of JOP20210147A1 publication Critical patent/JOP20210147A1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOP/2021/0147A 2018-12-21 2019-12-20 صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه JOP20210147A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
JOP20210147A1 true JOP20210147A1 (ar) 2023-01-30

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0147A JOP20210147A1 (ar) 2018-12-21 2019-12-20 صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه

Country Status (23)

Country Link
US (2) US12297179B2 (enExample)
EP (1) EP3898597A1 (enExample)
JP (3) JP2022515239A (enExample)
KR (1) KR20220035022A (enExample)
CN (1) CN113508108B (enExample)
AU (1) AU2019403396B2 (enExample)
BR (1) BR112021012305A2 (enExample)
CA (1) CA3124401A1 (enExample)
CL (1) CL2021001640A1 (enExample)
CO (1) CO2021009309A2 (enExample)
CR (1) CR20210394A (enExample)
GE (2) GEAP202415700A (enExample)
IL (1) IL284218B1 (enExample)
JO (1) JOP20210147A1 (enExample)
MA (1) MA54541A (enExample)
MX (1) MX2021007536A (enExample)
NI (1) NI202100055A (enExample)
PE (2) PE20212197A1 (enExample)
PH (1) PH12021551495A1 (enExample)
SG (1) SG11202106526UA (enExample)
TW (1) TWI875727B (enExample)
UA (1) UA130491C2 (enExample)
WO (1) WO2020132471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9012464B2 (en) * 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
TWI818954B (zh) * 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
CA3184024A1 (en) * 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Also Published As

Publication number Publication date
NI202100055A (es) 2021-12-01
MX2021007536A (es) 2021-09-23
BR112021012305A2 (pt) 2021-10-05
GEAP202415700A (en) 2024-05-13
JP7749080B2 (ja) 2025-10-03
TWI875727B (zh) 2025-03-11
CA3124401A1 (en) 2020-06-25
CN113508108B (zh) 2024-12-24
AU2019403396A1 (en) 2021-07-08
CL2021001640A1 (es) 2022-06-03
CN113508108A (zh) 2021-10-15
KR20220035022A (ko) 2022-03-21
US12297179B2 (en) 2025-05-13
IL284218A (en) 2021-08-31
WO2020132471A1 (en) 2020-06-25
US20250270175A1 (en) 2025-08-28
PH12021551495A1 (en) 2022-03-07
JP2026001058A (ja) 2026-01-06
SG11202106526UA (en) 2021-07-29
UA130491C2 (uk) 2026-03-04
CO2021009309A2 (es) 2021-10-29
WO2020132471A8 (en) 2020-08-06
PE20212197A1 (es) 2021-11-16
PE20260309A1 (es) 2026-02-11
AU2019403396B2 (en) 2024-12-12
GEP20247683B (en) 2024-10-28
EP3898597A1 (en) 2021-10-27
MA54541A (fr) 2022-03-09
JP2024161431A (ja) 2024-11-19
US20220055995A1 (en) 2022-02-24
TW202039448A (zh) 2020-11-01
JP2022515239A (ja) 2022-02-17
IL284218B1 (en) 2026-01-01
CR20210394A (es) 2021-12-13

Similar Documents

Publication Publication Date Title
MX2024008497A (es) Fabricacion de compuestos y composiciones para inhibir la actividad de shp2.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
EA201690094A1 (ru) Ингибиторы syk
MX2020007265A (es) Derivados de rapamicina.
PH12021551495A1 (en) Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
JOP20190217B1 (ar) مركبات جديدة كمثبطات أوتوتاكسين وتركيبات صيدلانية تشتمل على هذه المركبات
EA201890752A1 (ru) Способ получения противогрибковых соединений
CA2875877C (en) Syk inhibitors
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX390748B (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2018001991A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
EA201891770A1 (ru) Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм
MY207239A (en) Imidazopyridinone compound
WO2018125983A8 (en) Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
EA201690755A1 (ru) Солевые и кристаллические формы ингибитора plk-4
PH12020500432A1 (en) Compounds and methods for treating hyperkalemia
CY1118552T1 (el) Νεα παραγωγα πυριμιδινης ως αναστολεις φωσφοδιεστερασης 10 (pde-10)
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب